Pancreatic cancer is amongst the deadliest cancers in the world. It is associated with poor prognosis, is notorious for developing chemoresistance, and very few approved chemotherapeutics are available to treat this disease. The natural compound pancratistatin (PST) has shown to effectively induce cytotoxicity selectively in numerous cancer cell types. However, it is present in only minute quantities in its natural source and many complications have burdened its chemical synthesis. We have overcome these bottlenecks by synthesizing a C-1 acetoxymethyl analogue of 7-deoxypancratistatin, JC-TH-acetate-4 (JCTH-4), which we have shown to have similar selective anti-cancer activity to that of PST. In this report, we show JCTH-4 to be a potent chemotherapeutic against pancreatic cancer cells (BxPC-3, PANC-1). It induced apoptosis selectively in BxPC-3 and PANC-1 cells by targeting the mitochondria; it dissipated mitochondrial membrane potential, caused release of apoptogenic factors, and in isolated mitochondria, increased the generation of reactive oxygen species. Furthermore, JCTH-4 selectively induced autophagy in pancreatic cancer cells while normal human fetal fibroblasts were markedly less sensitive to JCTH-4 insult. Altogether, this study outlines JCTH-4 as a potentially safe and effective chemotherapeutic agent in treating notoriously chemoresistant pancreatic cancer.
Introduction
Type I programmed cell death or apoptosis induction can arise extrinsically, as a result of death receptor ligation at the plasma membrane or intrinsically, as a response to internal cellular stress [1] . Such internal stress, including DNA damage, triggers upregulation of proapoptotic proteins which cause permeabilization of the mitochondrial membrane, dissipation of mitochondrial membrane potential (MMP), and release of apoptogenic factors [2, 3] . Once released from the mitochondria, these factors can execute apoptosis directly or indirectly via activation of caspases, a family of cysteine proteases [2, 3] .
Alternatively, type II programmed cell death, or autophagic cell death, results from the extensive activation of autophagy, a process which normally functions as a pro-survival stress response that allows cells to persist under unfavourable conditions [4] . Autophagy can be triggered by various forms of cellular stress such as oxidative stress, dysfunctional organelles, deficiencies in growth factors and nutrients, hypoxia, and pathogens [5] . Upon autophagic induction a membrane sac, a phagophore, engulfs portions of cytoplasm containing proteins and organelles to be degraded [6] . This gives rise to double-membrane vesicles termed autophagosomes which subsequently fuse with lysosomes to yield autolysosomes; previously engulfed contents are then degraded via lysosomal hydrolases [6] . Avoidance of programmed cell death has been implicated in cancer etiology and restoration or selective induction of these pathways may prove to be advantageous strategies in cancer therapy [7, 8] .
Pancreatic cancer is notoriously one of the most deadly cancers worldwide [9, 10] . Most patients are diagnosed at advanced stages of this disease and consequently few live longer than 6 months post diagnosis [11, 12] . The standard therapy for pancreatic cancer has been gemcitabine, increasing quality of life and survival time [13] . However, the largest obstacles in combating this malignancy are inherent and developed resistance against chemotherapy [14, 15] . Currently, there are only a few other approved chemotherapeutic agents available for treating pancreatic cancer, and thus, it would be invaluable to find and develop novel compounds with greater efficacy and specificity towards these malignancies.
In preceding studies, we have reported the Amaryllidaceae alkaloid pancratistatin (PST) to induce apoptosis selectively in a variety of cancer cell types at low doses and decrease the volume of human tumors in vivo; PST is well tolerated in mice and non-cancerous cells are drastically less sensitive to this compound [16] [17] [18] [19] [20] [21] [22] . Nevertheless, the availability of this compound has impeded its preclinical and clinical work; PST is present in only minuscule quantities in the Hymenocallis littoralis plant and many difficulties have been encountered with its chemical synthesis. To overcome these issues, we have produced 7-deoxypancratistatin derivatives via chemoenzymatic synthesis from bromobenzene and have screened them for similar anti-cancer activity; one C-1 acetoxymethyl analogue, JC-THacetate-4 (JCTH-4), was identified to have comparable efficacy and specificity to PST in several cancer cell types [23] . Herein, we report JCTH-4 to be an effective inducer of apoptosis and autophagy selectively in pancreatic cancer cells. Such activity in pancreatic cancer may be attributed to mitochondrial targeting by JCTH-4; this compound caused the release of apoptogenic factors from the mitochondria, dissipated mitochondrial membrane potential, and in isolated mitochondria, increased the production of reactive oxygen species (ROS). Such cytotoxicity was not observed in normal human fetal fibroblasts (NFF). Thus, these results present JCTH-4 as a potential selective and potent chemotherapeutic against pancreatic cancer.
Materials and Methods

Cell Culture
A pancreatic adenocarcinoma cell line, 
Cell Treatment
In this study, cells were cultured to 60-70 % confluence and subsequently treated with tamoxifen (TAM) citrate salt (Sigma-Aldrich Canada, Cat. No. T9262, Mississauga, ON, Canada), the broad spectrum caspase inhibitor Z-VAD-FMK (EMD Chemicals, Gibbstown, NJ, USA), and JC-TH-acetate-4 (JCTH-4) at the indicated concentrations and durations. As previously described, JCTH-4 was created by chemoenzymatic synthesis from bromobenzene [23] .
Compounds were dissolved in dimethylsulfoxide (Me 2 SO).
Nuclear Staining
Following treatment and incubation with the aforementioned drugs, cells were incubated with 10 µM Hoechst 33342 dye (Molecular Probes, Eugene, OR, USA) for 5 minutes to visualize the nuclei. Images were aquired at 400x magnification on a Leica DM IRB inverted fluorescence microscope (Wetzlar, Germany).
Annexin V Binding Assay
The Annexin V binding assay was carried out to validate apoptosis. After drug treatment, cells were washed with phosphate buffer saline (PBS) 
Tetramethylrhodamine Methyl Ester (TMRM) Staining
To detect MMP, tetramethylrhodamine methyl ester (TMRM) (Gibco BRL, VWR, Mississauga, ON, Canada) was used. Cells were grown on coverslips and treated with JCTH-4 at the indicated concentrations and for the indicated durations. After treatment, cells were incubated with 200 nM TMRM for 45 minutes at 37˚ C. Fluorescent micrographs were taken at 400x magnification on a Leica DM IRB inverted fluorescence microscope (Wetzlar, Germany).
Mitochondrial Isolation
Mitochondria were isolated from untreated BxPC-3 cells. BxPC-3 cells were washed two times in cold PBS, resuspended in hypotonic buffer (1 mM EDTA, 5 mM Tris-HCl, 210 mM mannitol, 70 mM sucrose, 10 μM Leu-pep, 10 μM Pep-A, and 100 μM PMSF), homogenized, and centrifuged at 600 x g for 5 minutes at 4˚ C. The supernatant was centrifuged at 15,000 x g for 15 minutes at 4˚ C. The resulting cytosolic supernatant was discarded and the mitochondrial pellet was resuspended in cold reaction buffer (2.5 mM malate, 10 mM succinate, 10 μM Leu-pep, 10 μM Pep-A, and 100 μM PMSF in PBS).
Amplex Red Assay
ROS production was measured with Amplex Red (Molecular Probes, Eugene, OR, USA). Isolated mitochondria suspended in cold reaction buffer were loaded into wells of an opaque 96-well plate (20 µg of protein/well) with the indicated concentrations of drugs. Paraquat (PQ) (Sigma-Aldrich Canada, Mississauga, ON, Canada) was used as a positive control at 250 µM. Amplex Red reagent was added to each well at a final concentration of 50 µM and horseradish peroxidase (HRP) (Sigma-Aldrich Canada, Mississauga, ON, Canada) was added in the ratio of 6 U/200 µL. Fluorescence readings were taken after 2 hours of incubation at Ex. 560 nm and Em. 590 nm on a spectrofluorometer (SpectraMax Gemini XS, Molecular Devices, Sunnyvale, CA, USA). Fluorescence readings were expressed as relative fluorescence units (RFU).
Cellular Lysate Preparation
After 72 hours of treatment with the indicated concentrations of JCTH-4 and TAM, cells were manually homogenized in cold hypotonic buffer (10 mM Tris HCl at pH 7.2, 5 mM KCl, 1 mM MgCl 2 , 1 mM EGTA, 1% Triton-X-100; 10 μM Leu-pep, 10 μM Pep-A, and 100 μM PMSF). Cell lysates were stored at -20˚ C until use.
Western Blot Analyses
Protein samples were subjected to SDS-PAGE and transferred to a nitrocellulose membrane. Membranes were blocked with a 5% w/v milk TBST (Tris-Buffered Saline with Tween-20) solution for 1 hour and probed overnight at 4˚ C with either: an anti-LC3 antibody raised in rabbits (1:500) (Novus Biologicals, Cat. No. NB100-2220, Littleton, CO, USA), an anti-β-Actin antibody raised in mice (1:1000) (Santa Cruz Biotechnology, Inc., Cat. No. sc-81178, Paso Robles, CA, USA), an anticytochrome C (Cyto C) antibody raised in mice 
Monodansylcadaverine (MDC) Staining
Monodansylcadaverine (MDC) (SigmaAldrich Canada, Mississauga, ON, Canada) was used to visualize autophagic vacuoles. Cells were grown on coverslips and treated with the indicated concentrations of drugs and durations. Subsequent to drug treatment, cells were incubated with 0.1 mM MDC for 15 minutes. Micrographs were acquired at 400x magnification on a Leica DM IRB inverted fluorescence microscope (Wetzlar, Germany).
Propidium Iodide (PI) Staining
Cell lysis was observed using Propidium iodide (PI) dye (Sigma-Aldrich Canada, Mississauga, ON, Canada). For 10 minutes, cells were incubated with PI at a concentration of 1 μg/mL. Subsequently, micrographs were acquired with a Leica DM IRB inverted fluorescence microscope (Wetzlar, Germany) at 400x magnification. 
Results
JCTH-4 Selectively Induces Cytotoxicity in Pancreatic Carcinoma Cells in a Time & DoseDependent Manner
To circumvent the issues surrounding the low availability of PST ( Figure 1A ), a potent and selective inducer of cytotoxicity in numerous cancer cell types, synthetic analogues of PST were synthesized and evaluated for similar activity in BxPC-3 and PANC-1 pancreatic cancer cell lines. Using the WST-1 colorimetric assay for cell viability, it was found that JCTH-4 ( Figure 1B ), a C-1 acetoxymethyl analogue of 7-deoxypancratistatin, was able to effectively induce cytotoxicity in BxPC-3 and PANC-1 cells in a time and dose dependent manner (Figure 2A 
JCTH-4 Selectively Induces Apoptosis in Pancreatic Carcinoma Cells
Apoptotic morphology was observed in pancreatic cancer cells treated with JCTH-4 as seen with Hoechst nuclear staining and phase microscopy; cell shrinkage, blebbing, brightly stained and condensed nuclei, and apoptotic bodies were produced by JCTH-4 in BxPC-3 cells at 0.5 µM and 1 µM and in PANC-1 cells at 1 µM and 2 µM (Figure 3A and B) . Such morphology was absent in NFF cells treated with JCTH-4 ( Figure 3C ). Selective induction of apoptosis in pancreatic cancer cells was confirmed with the binding of Annexin V to exposed phosphatidylserine, a biochemical marker of apoptosis, as indicated by the green fluorescence ( Figure 3D-F) . These results illustrate JCTH-4 to be a potent and selective agent against BxPC-3 and PANC-1 cells via induction of apoptotic cell death. 
JCTH-4 Selectively Induces Apoptosis by Targeting Mitochondria in Pancreatic Carcinoma Cells
In previous reports, we have attributed the apoptosis-inducing capabilities of PST to mitochondrial targeting [17] [18] [19] [20] [21] [22] . Subsequent to mitochondrial membrane permeabilization, various apoptogenic factors are released from the mitochondria into the cytosol which can then directly or indirectly execute apoptosis [2] . To verify whether or not JCTH-4 is able to cause release of these factors, pancreatic cancer cells were treated with 1 µM JCTH-4 for 72 hours. Following treatment, cells were lysed and centrifuged to produce cytosolic and mitochondrial fractions that were analyzed for the release or retention of apoptogenic factors respectively with JCTH-4 insult. Indeed, JCTH-4 caused the release of the apoptogenic factors AIF and Cyto c from mitochondria of BxPC-3 cells and a decreased retention of the apoptogenic factor EndoG in PANC-1 mitochondria ( Figure  4D-F) . Complementary to these findings, isolated mitochondria from BxPC-3 cells were treated directly with 1 µM JCTH-4 for 2 hours, and exhibited an increase in ROS production, an indicator of mitochondrial dysfunction ( Figure  4G ). PQ was used as a positive control as it is known to induce ROS generation in mitochondria [24] . Collectively, these findings clearly demonstrate the mitochondria to be the target of JCTH-4.
Activity of JCTH-4 is Independent of Caspase Activation
Upon their expulsion from the mitochondria, apoptogenic factors can execute apoptosis directly or indirectly; factors such as AIF and EndoG are able to translocate to the nucleus to execute apoptosis directly while Cyto c activates a caspase signalling cascade to achieve apoptosis [2, 25, 26, 3] . To assess the involvement of caspases in JCTH-4-induced apoptosis, the broad spectrum caspase inhibitor Z-VAD-FMK was used in conjunction with 1 µM JCTH-4 on BxPC-3 cells for 72 hours. As seen using the WST-1 colorimetric assay for cell viability, the inhibitor was unable to protect the BxPC-3 cells from JCTH-4, demonstrating a caspase-independent mode of action ( Figure 5 ). 
Selective Autophagic Induction Occurs in Pancreatic Carcinoma Cells Treated with JCTH-4
Both pro-death and pro-survival autophagic responses have been implicated with chemotherapeutic insult [4] . As JCTH-4 causes oxidative stress in pancreatic cancer cells, a known inducer of autophagy, we monitored pancreatic cancer cells for autophagic induction. PANC-1 cells were treated with TAM, a known inducer of autophagy as a positive control, and JCTH-4 at 1 and 2 µM for 72 hours and stained with MDC, an indicator of autophagosomes. Bright blue punctate MDC staining was present in cells treated with JCTH-4, comparable to the TAM treated cells ( Figure 6A ). PANC-1 cells were also stained with PI, but none of the aforementioned treatments yielded positive PI staining ( Figure 6A) . Interestingly, JCTH-4 did not induce autophagy in NFF cells as seen with MDC staining (Figure 6B ).
The conversion of microtubule-associated protein1 light chain 3 (LC3) localized in the cytosol as LC3-I, to LC3-II which is recruited to autophagosomal membranes occurs with the induction of autophagy [27] . To validate autophagic induction by JCTH-4 in PANC-1 cells, western blot analyses were performed on cell lysates of PANC-1 cells treated with 1 µM JCTH-4 for 72 hours to analyze the conversion of LC3-I to LC3-II; this conversion was observed with JCTH-4 treatment and produced at greater autophagic response than the TAM treated cells used as a positive control ( Figure 6C ). Thus, JCTH-4 is capable of selectively inducing apoptosis in pancreatic cancer cells. 
Discussion
Currently, pancreatic cancer stands as one of the most fatal malignancies in the world [9, 10] . As this disease lacks distinct and evident symptoms, it is difficult to diagnose in its early stages. Thus, pancreatic cancer is often found in its advanced stages with most patients showing metastases to the liver, lungs, or proximal lymph nodes at the time of diagnosis [11, 12] . Very few anti-cancer drugs are available for the treatment of this disease as most standard chemotherapeutics have been shown to be ineffective; doxorubicin, 5-5-fluorouracil, and cisplatin have been shown to be ineffective both in vitro and in vivo [28] . The nucleoside analogue gemcitabine has been shown to be moderately effective and currently serves as the standard chemotherapeutic treatment for pancreatic cancer [29] . Despite various efforts to enhance the effectiveness of this drug with other chemotherapeutics such as erlotinib, gemcitabine still remains only moderately potent against pancreatic cancer and is often rendered ineffective with the onset of chemoresistance [30, 29] . Consequently, the necessity for a more potent treatment presently remains unfulfilled.
In this study, we report the activity of a synthetic analogue of PST, JCTH-4, against human pancreatic cancer cells. JCTH-4 was able to effectively induce cytotoxicity in the BxPC-3 and PANC-1 pancreatic cancer cells by way of apoptotic induction in a selective manner. Necrotic cell death, characterized by lysis of the plasma membrane, by JCTH-4 was ruled out as cells subjected to JCTH-4 were negative for PI staining, a DNA stain impermeable to the plasma membrane ( Figure 6A ) [31] . The genotoxic drug gemcitabine is the only chemotherapeutic that has shown moderate effectiveness against pancreatic cancer. Giroux et al., 2006 demonstrated that gemcitabine is effective in BxPC-3 cells at submicromolar concentrations; however, the effectiveness of this drug quickly plateaus as the dose is increased [29] . Furthermore, they observed that PANC-1 cells have minimal sensitivity to gemcitabine with an IC 50 value of 25 µM after 72 hours [29] . In contrast, the IC 50 values for BxPC-3 and PANC-1 cells were 0.25 µM and 0.5 µM respectively after 72 hours (Figure 2A & 2B) .
Thus, JCTH-4 is more effective against both BxPC-3 and PANC-1 cells than gemcitabine. Similar to PST, JCTH-4 is selective against cancer cells as we have previously shown minimal toxicity in normal human fibroblasts and noncancerous peripheral blood mononuclear cells [23] . Additionally, in this study NFF cells proved to be markedly less sensitive to JCTH-4 compared to both BxPC-3 and PANC-1 cells (Figure 2C ), did not exhibit any observable signs of apoptotic induction ( Figure 3F ), and were not affected in terms of their dividing capacity after removal of JCTH-4 (Data not shown). On the contrary, other chemotherapeutics currently available such as Taxol and VP-16 have been shown to produce cytotoxicity in normal human fibroblasts at their effective doses [17] . Thus, these findings illustrate JCTH-4 to be a potentially more effective chemotherapeutic alternative to current cancer therapies.
Previously, we have shown the natural compound PST to be a potent and selective anticancer agent; PST was able to induce apoptosis in numerous cancer cell types with minimal cytotoxicity in non-cancerous cells [16] [17] [18] [19] [20] . Furthermore, PST was able to decrease the volume of human tumor xenografts in vivo and was nontoxic to mice [21, 22] . PST however, is only present in parts per million quantities in the buds of the Hymenocallis littoralis plant and many difficulties have burdened its chemical synthesis.
In an attempt to circumvent these issues, we subsequently synthesized various analogues of PST and found similar anti-cancer activity with JCTH-4 in human neuroblastoma and leukemia cell lines, with no evident toxicity to various noncancerous cell types [23] . The findings presented in this study demonstrate JCTH-4 to also be a potent agent against BxPC-3 and PANC-1 cells, two different cell lines of a very aggressive and deadly cancer. Thus, previous limitations hindering the preclinical and clinical work with PST have been surpassed.
As with PST, our results outline the mechanistic target of JCTH-4 to be the mitochondria; JCTH-4 was shown to dissipate MMP ( Figure 4A & B) , cause the release of apoptogenic factors from the mitochondria ( Figure  4D & E) , and in isolated mitochondria, increase ROS production ( Figure 4G ). Such mitochondrial targeting was not evident in NFF cells ( Figure  4C ), complementing previous work with PST; mitochondrial ROS production selectively increased in isolated mitochondria of cancer cells but not in normal human fibroblast mitochondria with PST treatment [17] . In response to various forms of cellular stress, the tumor suppressor p53 transcriptionally activates various proapoptotic proteins that can give rise to mitochondrial membrane permeabilization [32] . Although moderately differing in sensitivities, both BxPC-3 and PANC-1, two different p53-mutated pancreatic cancer cell lines, were responsive to JCTH-4 [33, 34] . Thus, signalling of p53 and its transcriptional targets, all of which are cellular events upstream of mitochondrial permeabilization, play an insignificant role in JCTH-4-induced apoptosis, supporting the notion of a direct mitochondrial target by JCTH-4. The caspase-independent nature of JCTH-4-induced apoptosis ( Figure 5) further supports mitochondrial targeting by JCTH-4 as caspase signalling can occur upstream of the mitochondria to permeabilize it. Although caspases are required for the execution apoptosis through Cyto c, JCTH-4 may yield apoptosis through the release of other apoptogenic factors such as AIF and EndoG which can directly execute apoptosis in a caspaseindependent manner [2, 25, 26, 3] .
Various differences exist between normal and cancer cell mitochondria which may serve as the basis by which JCTH-4 targets cancer cells specifically. The Warburg effect, a phenomenon in which cancer cells rely heavily on glycolysis for ATP generation, is postulated to be a result of mitochondrial dysfunction [35] . It is therefore possible for JCTH-4 to target these differences in metabolism. Moreover, an acidic cytosolic environment is created as result these alterations in metabolic activity which in part contributes to elevated MMP in cancer cell mitochondria. Heightened MMP in cancer cell mitochondria has been linked to an increased capacity to evade apoptosis, invade neighbouring tissue, and promote angiogenesis [36] . It is this elevation in MMP however, that may be exploited by JCTH-4 for cancer selectivity. Upon entering the cell, JCTH-4 may acquire as positive charge through enzymatic processing which may then be preferentially taken up selectively by cancer cell mitochondria as a result of their increased MMP. Additionally, cancer cells have been reported to overexpress various proteins which act to inhibit mitochondrial outer membrane permeabilization such as antiapoptotic proteins of the Bcl-2 family, peripheral-type benzodiazepine, and hexokinase II [37] [38] [39] . All of these proteins could serve as potential targets of JCTH-4.
Cellular stress, such as oxidative stress, can trigger the induction of autophagy. As JCTH-4 was found to increase the production of ROS in isolated mitochondria of pancreatic cancer cells ( Figure 4G ), we monitored PANC-1 for autophagic induction following JCTH-4 insult. Indeed, autophagy was induced selectively in pancreatic cancer cells by JCTH-4 ( Figure 6A-C) . Increased ROS production triggered by JCTH-4-induced mitochondrial dysfunction is most likely responsible for selective autophagic induction in these pancreatic cancer cells, which provides additional evidence of a mitochondrial target by JCTH-4. Nevertheless, these cells ultimately die as a result of mitochondrial membrane permeabilization and the subsequent release of apoptogenic factors.
In summary, the novel analogue of PST, JCTH-4, is effective in inducing apoptosis and autophagy selectively in pancreatic cancer cells by means of mitochondrial targeting. Furthermore, this compound was shown to be very effective against one of the most aggressive and notoriously chemoresistant malignancies, surpassing its current standard chemotherapeutic agent in efficacy. Thus, the unprecedented activity of this compound presents a potentially safe and effective treatment for pancreatic cancer.
